Sarepta Therapeutics (NASDAQ:SRPT) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Thursday, Benzinga reports. The firm currently has a $166.00 price target on the biotechnology company’s stock.

SRPT has been the topic of several other research reports. Wedbush reiterated an outperform rating and issued a $224.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Mizuho upped their target price on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a buy rating in a report on Wednesday, February 14th. Royal Bank of Canada lifted their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an outperform rating in a research note on Thursday, February 29th. UBS Group upped their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a buy rating in a research note on Friday, March 1st. Finally, Barclays raised their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an overweight rating in a report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $160.60.

Sarepta Therapeutics Trading Up 2.3 %

NASDAQ:SRPT opened at $133.66 on Thursday. The company has a market cap of $12.63 billion, a PE ratio of 1,215.09 and a beta of 0.95. The company has a current ratio of 4.05, a quick ratio of 3.45 and a debt-to-equity ratio of 1.18. The company has a 50 day simple moving average of $125.63 and a two-hundred day simple moving average of $110.76. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. During the same quarter in the previous year, the company posted ($1.44) earnings per share. Sarepta Therapeutics’s revenue was up 63.1% compared to the same quarter last year. Research analysts forecast that Sarepta Therapeutics will post 2.23 earnings per share for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,096 shares of company stock valued at $2,739,419. Corporate insiders own 7.40% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. Vanguard Group Inc. grew its holdings in shares of Sarepta Therapeutics by 0.5% in the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock valued at $1,039,212,000 after purchasing an additional 41,465 shares in the last quarter. Picton Mahoney Asset Management purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter worth $2,576,000. WCM Investment Management LLC bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth about $600,000. Capula Management Ltd purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at about $1,409,000. Finally, State of New Jersey Common Pension Fund D lifted its holdings in shares of Sarepta Therapeutics by 8.2% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,398 shares of the biotechnology company’s stock valued at $4,956,000 after acquiring an additional 3,912 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.